Viking Therapeutics

205 articles about Viking Therapeutics

• Viking Therapeutics Announces Closing Of Public Offering Of Common Stock And Warrants

  4/14/2016

• Viking Therapeutics Presents Positive Phase 1b Clinical Data On VK2809 In Hypercholesterolemic Subjects

  4/11/2016

• Viking Therapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants

  4/8/2016

• Viking Therapeutics Reports Fourth Quarter And Year-End 2015 Financial Results And Provides Corporate Update

  3/9/2016

• Viking Therapeutics To Present At Upcoming Investor Conferences

  2/2/2016

• Viking Therapeutics To Present At Biotech Showcase 2016

  1/7/2016

• Viking Therapeutics Presents New Data On VK5211 Demonstrating Robust Weight Gain In Primates Following 13 Weeks Of Treatment

  12/7/2015

• Viking Therapeutics And Kennedy Krieger Institute Sign Collaboration Agreement To Evaluate Novel Thyroid Beta Agonists For X-Linked Adrenoleukodystrophy (X-ALD)

  11/23/2015

• Viking Therapeutics Submits Investigational New Drug (IND) Application To Conduct Phase 2 Clinical Trial Of VK2809 In Patients With Hypercholesterolemia And Fatty Liver Disease

  11/17/2015

• Viking Therapeutics To Present At Upcoming Life Science Industry Events

  11/12/2015

• Viking Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update

  11/5/2015

• Viking Therapeutics Initiates Phase 2 Trial Of VK5211 In Patients Recovering From Hip Fracture

  11/3/2015

• Viking Therapeutics Completes Safety, Tolerability And Pharmacokinetic Study Of VK5211, A Selective Androgen Receptor Modulator (SARM), In Healthy Elderly Subjects

  10/20/2015

• Viking Therapeutics To Present At Upcoming Investor Conferences

  10/5/2015

• Viking Therapeutics Initiates Clinical Trial For VK5211, A Selective Androgen Receptor Modulator (SARM), For Acute Hip Fracture

  9/1/2015

• Viking Therapeutics Reports Second Quarter 2015 Financial Results And Provides Corporate Update

  8/13/2015

• Viking Therapeutics To Conduct Phase II Trial Of VK2809 In Patients With Cholesterolemia And Fatty Liver Disease

  7/29/2015

• Viking Therapeutics Submits Investigational New Drug (IND) Application For VK5211, A Selective Androgen Receptor Modulator (SARM), In Acute Hip Fracture

  7/14/2015

• Viking Therapeutics Announces Chairman Appointment

  6/5/2015

• Ligand Pharmaceuticals Inc. Summarizes The Accounting Impact Of The Viking Therapeutics IPO And Updates 2015 Financial Guidance

  6/3/2015